Document ID: chunk:federal_register_of_legislation:F2021L00216:reg:7
Version: federal_register_of_legislation:F2021L00216
Segment Type: reg
Provision Reference: reg 7
Character Range: 1752–3348

7               Kind of injury, disease or death to which this Statement of Principles relates
(1)          This Statement of Principles is about acute lymphoblastic leukaemia/lymphoblastic lymphoma and death from acute lymphoblastic leukaemia/lymphoblastic lymphoma.
Meaning of acute lymphoblastic leukaemia/lymphoblastic lymphoma
(2)          For the purposes of this Statement of Principles, acute lymphoblastic leukaemia/lymphoblastic lymphoma:
(a)          means a malignant neoplasm characterised by the clonal proliferation of morphologically immature, non-functioning lymphoid cells of B- or T-cell origin, which can present clinically as either a leukaemia or a lymphoma; and
(b)           excludes:
                (i)            Burkitt leukaemia/lymphoma;
                (ii)         adult T-cell leukaemia/lymphoma;
                (iii)       acute undifferentiated leukaemia; and
                (iv)        indolent T‑lymphoblastic proliferation.
            Note: Acute lymphoblastic lymphoma and lymphoblastic leukaemia are considered to be tumours of the same lymphoid cell type, and are considered to be a single disease entity with two clinical presentations.
Death from acute lymphoblastic leukaemia/lymphoblastic lymphoma
(3)          For the purposes of this Statement of Principles, acute lymphoblastic leukaemia/lymphoblastic lymphoma, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's acute lymphoblastic leukaemia/lymphoblastic lymphoma.
Note: terminal event is defined in the Schedule 1 - Dictionary.